ISORAY INC (ISR)
US46489V1044 - Common Stock
Perspective Therapeutics Expands Management Team And Names Andrew Bright as Executive Vice-President of Brachytherapy
The appointment advances Perspective Therapeutics’ journey to become a global leader in the manufacturing and distribution of therapeutic Cesium-131...
Perspective Therapeutics Announces the Awarding of a $1 million Collaborative Grant to King’s College London to Support Radiobiology Research of Alpha Particle Therapy for Cancer
The grant from the Medical Research Council (MRC) of the United Kingdom (part of UK Innovation and Research; UKRI) is supporting preclinical in vitro and...
Initial Results From First Patient Dosed With Perspective Therapeutics’ Lead Drug VMT-α-NET Presented at The Treatment of Neuroendocrine Disorders at the 2023 PET/RTRC Annual Workshop Scientific Session
The result from first patient dosed with VMT-α-NET in India on a compassionate use basis showed favorable responses. The initial response was measured by a...
Perspective Therapeutics (formerly known as Isoray, Inc.) Announces Financial Results for the Quarter ended December 31, 2022
Fiscal Calendar Year Changes from June to December Year End...
Isoray Inc. and Viewpoint Molecular Targeting Inc. Announce Name Change to Perspective Therapeutics Inc.
Company’s focus is on the advancement of cancer treatments using radiation, radiopharmaceuticals, and imaging technologies New corporate tagline and...
Isoray Completes Merger with Viewpoint Molecular Targeting to Advance New Treatment Paradigm in Targeted Precision Oncology Medicine
Isoray Announces Results of Fiscal 2023 Annual Meeting of Stockholders
Stockholders Approve Proposal One Clearing Way for Consummation of Merger...
Isoray Announces Adjournment of Annual Meeting of Stockholders to January 27, 2023
RICHLAND, Wash., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy...
AMENDED: Isoray Announces Adjournment of Annual Meeting of Stockholders to January 12, 2023
RICHLAND, Wash., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy...
Isoray Announces Adjournment of Annual Meeting of Stockholders to January 12, 2022
RICHLAND, Wash., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy...
ISORAY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Isoray, Inc - ISR
Isoray Announces First Quarter Fiscal 2023 Financial Results and Provides Update to Pending Merger
RICHLAND, Wash., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy...
Isoray To Announce First Quarter Fiscal 2023 Financial Results on November 10, 2022
Conference Call is Thursday, November 10, 2022 at 4:30 p.m. ET/1:30 p.m. ...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TALO, ISR, FCRD, SESN
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Isoray Medical, Inc. and Viewpoint Molecular Targeting, Inc. Announce Investor Webcast on October 19, 2022 at 4:15 p.m. EDT
ISR Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Isoray, Inc. Is Fair to Shareholders
Isoray Announces Transformational Merger and Fourth Quarter and Full-Year Fiscal Year End 2022 Financial Results
RICHLAND, Wash., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy,...
Isoray To Announce Fourth Quarter and Fiscal Year End 2022 Financial Results on September 28, 2022
Conference Call is Wednesday, September 28 at 4:30 p.m. ET/1:30 p.m. ...
Isoray’s Cesium-131 Featured in Presentations at American Brachytherapy Society’s Annual Conference
RICHLAND, Wash., June 21, 2022 (GLOBE NEWSWIRE) -- The growing body of information regarding Isoray, Inc.’s (NYSE American: ISR) Cesium-131 in treating...
Isoray To Host Lunch Symposium At American Brachytherapy Society’s Annual Conference
RICHLAND, Wash., June 15, 2022 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy,...
Isoray Announces Record Third Quarter Fiscal 2022 Financial Results
Revenue Increased 12% Year-Over-YearRecord Non-Prostate Brachytherapy Revenue Increased 28% Year-Over-Year RICHLAND, Wash., May 10, 2022 (GLOBE...
Isoray To Announce Third Quarter Fiscal 2022 Financial Results on May 10, 2022
Conference Call is Tuesday, May 10, 2022 at 4:30 p.m. ET/1:30 p.m. ...
Isoray to Participate in the Oppenheimer 32nd Annual Healthcare Conference
RICHLAND, Wash., March 10, 2022 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE American: ISR), a medical technology company and innovator in seed brachytherapy,...
Study Finds Excellent Outcomes for Intermediate Risk Prostate Cancer Patients Treated with Isoray’s Cesium-131
RICHLAND, Wash., March 02, 2022 (GLOBE NEWSWIRE) -- Investigators from the University of Pittsburgh School of Medicine have published a clinical study...
Isoray Announces Second Quarter Fiscal 2022 Financial Results
Revenue Increased 19% Year-Over-YearProstate Brachytherapy Revenue Increased 13% Year-Over-Year RICHLAND, Wash., Feb. 08, 2022 (GLOBE NEWSWIRE) --...
Isoray To Announce Second Quarter Fiscal 2022 Financial Results on February 8, 2022
Conference Call is Tuesday, February 8, 2022 at 4:30 p.m. ET/1:30 p.m. ...